Navigation Links
Cancer stem cells similar to normal stem cells can thwart anti-cancer agents

Current cancer therapies often succeed at initially eliminating the bulk of the disease, including all rapidly proliferating cells, but are eventually thwarted because they cannot eliminate a small reservoir of multiple-drug-resistant tumor cells, called cancer stem cells, which ultimately become the source of disease recurrence and eventual metastasis. Now, research by scientists at the University of Pittsburgh School of Medicine suggests that for chemotherapy to be truly effective in treating lung cancers, for example, it must be able to target a small subset of cancer stem cells, which they have shown share the same protective mechanisms as normal lung stem cells. They are presenting this ground-breaking research at the Tissue Engineering and Regenerative Medicine International Society (TERMIS) North American Chapter meeting being held June 13 to 16 at the Westin Harbor Castle conference center in Toronto.

The University of Pittsburgh researchers, led by Vera Donnenberg, Ph.D., assistant professor of surgery and pharmaceutical sciences, University of Pittsburgh Schools of Medicine and Pharmacy, used cell surface markers and dyes to identify cancer stem cells as well as normal adult stem cells and their progeny in samples obtained from normal lung and lung cancer tissue samples. The researchers identified a very small, rare set of resting cancer stem cells in the lung cancer samples that looked and behaved much like normal adult lung tissue stem cells. Both the cancer and normal stem cells were protected equally by multiple drug resistance transporters, even if the bulk of the tumor responded to chemotherapy.

According to Dr. Donnenberg, the very fact that cancers can and do relapse after apparently successful therapy indicates the survival of a drug-resistant, tumor-initiating population of cells in many types of refractory cancers. “Because of the similarities between the way that normal stem cells and cancer stem cells protect themselves, ca ncer therapies have to be designed specifically to target cancer stem cells while sparing normal stem cells,” she explained.


Source:University of Pittsburgh Schools of the Health Sciences

Related biology news :

1. Adding Radiation Therapy To Chemotherapy Improves Survival In Patients With High-risk Breast Cancer
2. Jump-starting T Cells In Skin Cancer
3. Deficient DNA Repair Capacity Associated With Increased Risk Of Breast Cancer
4. Fox Chase Cancer Center scientists identify immune-system mutation
5. Breakthrough Microarray-based Technology for the Study of Cancer
6. Yale Scientists Find MicroRNA Regulates Ras Cancer Gene
7. Fundamental Finding Yields Insight into Stem Cells, Cancer; Opens Door to Drug Discovery
8. First-ever Compounds To Target Only Metastatic Cells Are Highly Effective Against Breast, Prostate, And Colon Cancers
9. Gene Vaccine Protects Mice Against Development Of Her2/neu Breast Cancer
10. New Breast Cancer Test Could Save Lives
11. Estrogen-like Component of Plastic Stimulates Growth of Certain Prostate Cancer Cells

Post Your Comments:

(Date:4/26/2016)... Research and Markets has announced ... 2016-2020"  report to their offering.  , ,     (Logo: ... analysts forecast the global multimodal biometrics market to ... period 2016-2020.  Multimodal biometrics is being ... the healthcare, BFSI, transportation, automotive, and government for ...
(Date:4/15/2016)... Research and Markets has announced ... 2016-2020,"  report to their offering.  , ... global gait biometrics market is expected to grow ... 2016-2020. Gait analysis generates multiple variables ... to compute factors that are not or cannot ...
(Date:3/31/2016)... Florida , March 31, 2016 ... ) ("LegacyXChange" or the "Company") LegacyXChange ... potential users of its soon to be launched online ... ( ) will also provide potential ... use of DNA technology to an industry that is ...
Breaking Biology News(10 mins):
(Date:6/23/2016)... , June 23, 2016   EpiBiome , ... secured $1 million in debt financing from Silicon Valley ... up automation and to advance its drug development efforts, ... new facility. "SVB has been an incredible ... the services a traditional bank would provide," said Dr. ...
(Date:6/23/2016)... Apellis Pharmaceuticals, Inc. today announced positive ... its complement C3 inhibitor, APL-2. The trials were ... studies designed to assess the safety, tolerability, pharmacokinetics ... healthy adult volunteers. Forty subjects were ... dose (ranging from 45 to 1,440mg) or repeated ...
(Date:6/23/2016)... CA (PRWEB) , ... June 23, 2016 , ... ... software, is exhibiting at the Pennsylvania Convention Center and will showcase its product’s ... conference. ClinCapture will also be presenting a scientific poster on Disrupting Clinical Trials ...
(Date:6/23/2016)... June 23, 2016 ... report to its pharmaceuticals section with historic and ... and much more. Complete report on ... pages, profiling 15 companies and supported with 261 ... . The Global Cell ...
Breaking Biology Technology: